Carcinoma Clinical Trial
Official title:
Identification of a Plasma Proteomic Signature for Lung Cancer
Verified date | January 2015 |
Source | Integrated Diagnostics |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Quorum Review IRB |
Study type | Observational |
The primary objective is to identify a panel of plasma and/or serum proteins that differentiates the absence or presence of lung malignancy in samples obtained from subjects enrolled in this IRB/EC approved study with pulmonary nodules.
Status | Completed |
Enrollment | 475 |
Est. completion date | December 2014 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - age = 40 - any smoking status, e.g. current, former, or never - co-morbid conditions, e.g. COPD - Nodule size = 4 mm and = 30 mm (up to Stage 2B eligible), any spiculation or ground glass opacity - Pathology: malignant - adenocarcinoma, squamous, or large cell - Pathology: benign - inflammatory (e.g. granulomatous, infectious) or non-inflammatory (e.g. hamartoma) - Clinical stage, Primary tumor: =T2 (e.g. 1A, 1B, 2A and 2B) - Clinical stage, Regional lymph nodes: N0 or N1 only - Clinical stage, Distant metastasis: M0 only Exclusion Criteria: - prior malignancy within 5 years of lung nodule diagnosis - No nodule size available - No pathology data available for those with - Current diagnosis of non-small cell lung cancer - Clinical stage: Primary tumor =T3; Regional lymph nodes: =N2; 4 Distant metastasis: =M1 |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | North East Alabama Regional Medical Center | Anniston | Georgia |
United States | Greater Baltimore Medical Center | Baltimore | Maryland |
United States | Lahey Hospital & Medical Center | Burlington | Massachusetts |
United States | University of Cincinnati | Cincinnati | Ohio |
United States | Cardiopulmonary Research Science and Technology Institute | Dallas | Texas |
United States | Geisinger Medical Center | Danville | Pennsylvania |
United States | Henry Ford Hospital | Detroit | Michigan |
United States | University of Miami - Sylvester Comprehensive Cancer Center | Miami | Florida |
United States | Intermountain Healthcare | Murray | Utah |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Kaiser Permanente Northern California | San Francisco | California |
United States | Group Health Research Institute | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Integrated Diagnostics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence rate of Non-Small Cell Lung Cancer | The incidence rate of non-small cell lung cancer in the study population will be correlated to the predictive value of the Sponsor's blood test. | 24 months after enrollment | No |
Secondary | Panel of proteins | The positive and negative predictive value of the test to differentiate between malignancy and inflammatory diseases such as granulomatous disorders. | At the end of the study | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05283226 -
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
|
Phase 2 | |
Active, not recruiting |
NCT04362072 -
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
|
Phase 4 | |
Completed |
NCT04033991 -
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
|
||
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT01942200 -
A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer
|
||
Completed |
NCT01061645 -
Study of MOC31-PE in Antigen Positive Carcinomas
|
Phase 1 | |
Completed |
NCT00532155 -
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
|
Phase 3 | |
Terminated |
NCT00557596 -
A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00216372 -
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
|
Phase 3 | |
Recruiting |
NCT06022757 -
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05520281 -
Short-term Psychodynamic Psychotherapy in Serious Physical Illness
|
N/A | |
Recruiting |
NCT05752357 -
The Role of Pre-operative and Post-operative Circulating Tumor Cells in Gastric Cancer.
|
||
Not yet recruiting |
NCT05023928 -
Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer
|
Phase 1 | |
Completed |
NCT00446446 -
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
|
Phase 2 | |
Recruiting |
NCT04566952 -
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06112041 -
The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
|
Phase 2 | |
Completed |
NCT03562897 -
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
|
Phase 2 | |
Recruiting |
NCT06013111 -
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors
|
Phase 1 |